20.44
0.48 (2.40%)
| Previous Close | 19.96 |
| Open | 19.67 |
| Volume | 658,041 |
| Avg. Volume (3M) | 413,184 |
| Market Cap | 950,359,488 |
| Price / Earnings (TTM) | 10.07 |
| Price / Sales | 1.43 |
| Price / Book | 1.24 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2026 |
| Profit Margin | 19.38% |
| Operating Margin (TTM) | 21.87% |
| Diluted EPS (TTM) | 2.76 |
| Quarterly Revenue Growth (YOY) | -0.80% |
| Quarterly Earnings Growth (YOY) | -41.40% |
| Total Debt/Equity (MRQ) | 86.86% |
| Current Ratio (MRQ) | 2.95 |
| Operating Cash Flow (TTM) | 193.17 M |
| Levered Free Cash Flow (TTM) | -3.71 M |
| Return on Assets (TTM) | 7.60% |
| Return on Equity (TTM) | 19.90% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Amphastar Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.38 |
|
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 23.68% |
| % Held by Institutions | 72.67% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Td Asset Management Inc | 31 Dec 2025 | 1,963,052 |
| Epoch Investment Partners, Inc. | 31 Dec 2025 | 1,126,585 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 30.00 (Needham, 46.77%) | Buy |
| 30.00 (Wells Fargo, 46.77%) | Buy | |
| Median | 30.00 (46.77%) | |
| Average | 30.00 (46.77%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 20.23 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Needham | 27 Feb 2026 | 30.00 (46.77%) | Buy | 20.23 |
| Wells Fargo | 27 Feb 2026 | 30.00 (46.77%) | Buy | 20.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Jan 2026 | Announcement | Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound |
| 07 Jan 2026 | Announcement | Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference |
| 15 Dec 2025 | Announcement | Amphastar Announces FDA Approval for Teriparatide Injection |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |